A long‐acting pegylated recombinant human growth hormone (Jintrolong®) in healthy adult subjects: Two single‐dose trials evaluating safety, tolerability and pharmacokinetics.
Summary: What is known and objective: Jintrolong® is a pegylated recombinant human growth hormone (rhGH) (PEG‐rhGH) developed for weekly subcutaneous (sc) injection. The current human tolerability trial and pharmacokinetics (PK) trial evaluated the safety, tolerability and PK of single‐dose Jintrolo...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 43; no. 5; pp. 640 - 647 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Wiley-Blackwell
Oct2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132092205&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 132092205 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02694727 EV4 jtl: Journal of Clinical Pharmacy & Therapeutics issn: 02694727 maglogo: Y pubinfo: dt: Oct2018 vid: 43 iid: 5 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 132092205 132092205 132092205 10.1111/jcpt.12732 132092205 ppf: 640 ppct: 7 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: A long‐acting pegylated recombinant human growth hormone (Jintrolong®) in healthy adult subjects: Two single‐dose trials evaluating safety, tolerability and pharmacokinetics. aug: au: Guan, Y. He, F. Wu, J. Zhao, L. Wang, X. Huang, L. Zeng, G. Ren, B. Chen, J. Liao, X. Ma, Z. Chen, X. Zhong, G. Huang, M. Zhao, X. affil: Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmaceutical Sciences, Sun Yat‐Sen University, Guangzhou, China sug: subj: Human Growth Hormone Administration and Dosage Human Growth Hormone Pharmacokinetics Drug Tolerance Patient Safety Injections, Intravenous Human Randomized Controlled Trials Adult Male Human Growth Hormone Blood Adult: 19-44 years Male ab: Summary: What is known and objective: Jintrolong® is a pegylated recombinant human growth hormone (rhGH) (PEG‐rhGH) developed for weekly subcutaneous (sc) injection. The current human tolerability trial and pharmacokinetics (PK) trial evaluated the safety, tolerability and PK of single‐dose Jintrolong® injection in healthy adult subjects. Methods: Both trials were single‐centre, randomized, open‐label and single‐dose studies. In the human tolerability trial, 34 healthy subjects were randomized to receive single‐dose Jintrolong® sc injection (0.01, 0.06, 0.2, 0.5 or 0.8 mg/kg) or placebo. In the PK study, 30 healthy male subjects were evenly randomized into 3 groups to receive single‐dose Jintrolong® sc injection (0.1, 0.2 or 0.4 mg/kg), and the subjects receiving 0.4 mg/kg Jintrolong® were given a single sc injection of conventional rhGH (0.067 mg/kg) after a 14‐day washout period. Safety and PK profiles of Jintrolong® were evaluated. Results and discussion: Jintrolong® was well tolerated with no serious adverse events or local injection responses. The PK trial showed that the plasma growth hormone concentration elevated quickly and stayed at peak level between 12 and 48 hours post‐Jintrolong® injection, then decreased gradually back to baseline within 168 hours. Compared to single‐dose conventional rhGH, Jintrolong® at all doses demonstrated significantly longer half time and time to maximum plasma concentration, lower clearance and higher systemic drug exposure, indicating prolonged presence of GH in the subjects’ circulation. Additionally, systemic exposure to Jintrolong® increased in a dose‐dependent manner. What is new and conclusion: Single‐dose Jintrolong® injection was well tolerated in healthy adult subjects, and the maximum tolerable dose was no lower than 0.8 mg/kg. Jintrolong® was long‐acting with the potential for weekly administration. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|